Gallbladder Cancer: Clinical Trials

20 trials for Gallbladder Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 2 recruiting, 1 terminated, 1 unknown. 20 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 120Completed 16, Recruiting 2, Terminated 1, Unknown 1
Phase 25Completed 3, Recruiting 1, Terminated 1

Follow Gallbladder Cancer: new trials by email Literature Review of Gallbladder Cancer trials Research Report on Gallbladder Cancer

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine - Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic
Phase 1RecruitingShanghai Zhongshan Hospital182026-05-012026-05-29
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
MDX2001 - Biliary Tract Cancer, Breast Cancer
Phase 1 / Phase 2RecruitingModeX Therapeutics, An OPKO Health Company3302024-06-122026-10-15
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma
Phase 1 / Phase 2CompletedTransThera Sciences (Nanjing), Inc.842022-04-132025-06-12
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma
Phase 1 / Phase 2CompletedTransThera Sciences (Nanjing), Inc.2032021-03-142024-04-26
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
Recombinant Human Interleukin-2, HER2Bi-Armed T Cells - Esophageal Cancer, Gastric Cancer
Phase 1UnknownYi Miao62016-02-012016-01-25
ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers
Acelarin, Cisplatin - Biliary Tract Cancer, Gallbladder Cancer
Phase 1CompletedThe Christie NHS Foundation Trust212016-01-012023-05-17
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin - Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Phase 1CompletedVanderbilt-Ingram Cancer Center282009-11-012017-07-02
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
Gemcitabine, Oxaliplatin, Sorafenib - Cholangiocarcinoma, Biliary Tract Cancer
Phase 1 / Phase 2TerminatedUniversity of Miami92009-08-012018-01-03
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
fluorouracil, irinotecan hydrochloride, leucovorin calcium - Anal Cancer, Carcinoma of the Appendix
Phase 1CompletedMayo Clinic72008-06-012017-05-25
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
PSMA/PRAME - Ovarian, Melanoma
Phase 1CompletedMannkind Corporation122007-02-012010-08-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
capecitabine, carboplatin, epirubicin hydrochloride - Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Phase 1CompletedUniversity of Nebraska462004-10-012024-01-03
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin - Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Phase 1CompletedUNC Lineberger Comprehensive Cancer Center232004-08-012012-03-07
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
gemcitabine hydrochloride, pemetrexed disodium - Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Phase 1 / Phase 2CompletedAlliance for Clinical Trials in Oncology682004-01-012016-12-07
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
TRICOM-CEA(6D) - Breast Cancer, Colorectal Cancer
Phase 1CompletedMichael Morse, MD142002-01-012014-09-08
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
motexafin gadolinium, radiation therapy - Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Phase 1CompletedUniversity of Pittsburgh1998-11-012016-01-18
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
fluorouracil, gemcitabine hydrochloride, leucovorin calcium - Colorectal Cancer, Esophageal Cancer
Phase 1CompletedNational Institutes of Health Clinical Center (CC)1081998-08-012012-03-23
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
irinotecan hydrochloride, oxaliplatin - Anal Cancer, Colorectal Cancer
Phase 1CompletedMemorial Sloan Kettering Cancer Center361998-04-012013-06-26
Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer
gemcitabine hydrochloride, polymerase chain reaction, immunohistochemistry staining method - Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Phase 1CompletedCity of Hope Medical Center161997-12-012015-06-08
Interleukin-12 in Treating Patients With Cancer in the Abdomen
Recombinant Interleukin-12 - Anal Cancer, Colorectal Cancer
Phase 1CompletedM.D. Anderson Cancer Center291997-08-012012-07-30
Biological Therapy in Treating Patients With Metastatic Cancer
CEA RNA-pulsed DC cancer vaccine - Breast Cancer, Colorectal Cancer
Phase 1CompletedDuke University241997-02-012013-02-22

Narrower conditions

Gallbladder Neoplasms (20)  ·  Pancreatic Neoplasms (13)  ·  Stomach Neoplasms (12)  ·  Bile Duct Neoplasms (11)  ·  Liver Neoplasms (11)  ·  Colonic Neoplasms (7)  ·  Biliary Tract Neoplasms (6)  ·  Carcinoma, Hepatocellular (6)  ·  Cholangiocarcinoma (6)  ·  Colorectal Neoplasms (6)  ·  Esophageal Neoplasms (6)  ·  Rectal Neoplasms (6)  ·  Small Cell Lung Carcinoma (5)  ·  Anus Neoplasms (4)  ·  Breast Neoplasms (4)

Broader conditions

Biliary Tract Diseases (20)  ·  Digestive System Diseases (20)  ·  Digestive System Neoplasms (20)  ·  Gallbladder Diseases (20)  ·  Neoplasms (20)  ·  Neoplasms by Site (20)  ·  Endocrine Gland Neoplasms (15)  ·  Endocrine System Diseases (15)  ·  Biliary Tract Neoplasms (14)  ·  Neoplasms by Histologic Type (14)  ·  Neoplasms, Glandular and Epithelial (14)  ·  Adenocarcinoma (13)  ·  Carcinoma (13)  ·  Gastrointestinal Diseases (13)  ·  Gastrointestinal Neoplasms (13)

Interventions

Gemcitabine (6)  ·  Oxaliplatin (4)  ·  Radiotherapy (3)  ·  Erlotinib Hydrochloride (2)  ·  Fluorouracil (2)  ·  Irinotecan (2)  ·  Leucovorin (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Amplified Fragment Length Polymorphism Analysis (1)  ·  Capecitabine (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Epirubicin (1)  ·  Immunohistochemistry (1)

Sponsors

TransThera Sciences (Nanjing), Inc. (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  City of Hope Medical Center (1)  ·  Duke University (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mannkind Corporation (1)  ·  Mayo Clinic (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Michael Morse, MD (1)  ·  ModeX Therapeutics, An OPKO Health Company (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  Shanghai Zhongshan Hospital (1)  ·  The Christie NHS Foundation Trust (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)  ·  University of Miami (1)

Countries

United States (15)  ·  China (3)  ·  United Kingdom (1)

Top investigators

Herbert K. Lyerly, MD (2)  ·  Bert H. O'Neil, MD (1)  ·  Eva Szabo, MD (1)  ·  Guoming Shi, MD, PhD (1)  ·  Jean L Grem, MD (1)  ·  Laura Goff, MD (1)  ·  Nancy E. Kemeny, MD (1)  ·  Peter Hosein, MD (1)  ·  Ramesh K. Ramanathan, MD (1)  ·  Renato Lenzi, MD (1)  ·  Robert McWilliams, MD (1)  ·  Sarina A. Piha-Paul, MD (1)  ·  Stephen I. Shibata, MD (1)  ·  Steven R. Alberts, MD (1)

Results publications

PMID 12196376, PMID 19023677, PMID 33210382, PMID 41495607

NIH funding

2015 (1), P30CA015083 (1), P30CA016086 (1), P30CA016672 (1), P30CA033572 (1), P30CA036727 (1), P30CA068485 (1), R21CA094523 (1)